Dietary (−)-Epicatechin supplementation regulates myofiber development, fillet quality, and antioxidant status of Yellow River carp (Cyprinus carpio)

Mi, Jiali; Liú, Dan; Qin, Chaobin; Yan, Xiao; Peng, Ping; Yun, Yinghao; Wang, Luming; Nie, Guoxing

doi:10.1016/j.aquaculture.2023.739542

Cited by 8 publications

(12 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven articles in this review verified an increase in the follistatin/myostatin ratio [ 37 , 39 , 42 , 43 , 48 , 54 , 57 ]. Taub et al [ 37 ] and Mafi et al [ 39 ] noted an increment in the follistatin levels but no significant differences in myostatin.…”

Section: Discussionmentioning

confidence: 77%

“…A reduced sample size was identified [ 37 , 42 , 43 ]; brief time assessment [ 40 ]; the data of the participant’s diet were not collected [ 41 , 42 ]; absence of an evaluation of EC consumption in different periods [ 37 , 38 , 39 , 40 , 41 , 42 , 45 , 46 , 48 , 49 , 50 , 51 , 54 , 55 , 57 , 58 , 59 , 60 , 61 ]; only one dose was studied [ 37 , 38 , 39 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 58 , 60 , 61 ]; absence of EC plasma concentrations [ 39 , 40 , 42 ,…”

Section: Resultsmentioning

confidence: 99%

“…Epicatechin supplementation has exhibited promising clinical applicability in the regeneration of muscle tissue [ 6 , 23 , 28 , 29 , 33 , 34 , 37 , 38 , 39 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ]. Thus, this systematic review intended to evaluate the effects of EC as dietary supplementation on skeletal muscle atrophy.…”

Section: Discussionmentioning

confidence: 99%

“…This systematic review showed the effect of epicatechin on increasing follistatin [ 37 , 39 , 42 , 43 , 48 , 54 ] and decreasing myostatin [ 9 , 34 , 37 , 39 , 42 , 48 , 57 ], activating mitochondrial biogenesis [ 42 , 47 , 49 , 59 ], and muscle capillary [ 45 , 46 , 47 , 49 ] due to VEGF stimulation [ 45 , 46 , 47 , 49 ]. In skeletal muscle, epicatechin suppresses the expression of atrogenes induced by FoxO [ 2 , 49 , 51 , 53 , 54 ] and improves muscle performance when combined with physical activity [ 52 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

“…In skeletal muscle, epicatechin suppresses the expression of atrogenes induced by FoxO [ 2 , 49 , 51 , 53 , 54 ] and improves muscle performance when combined with physical activity [ 52 , 54 ]. In addition, the major protein synthesis pathway (AKT/mTORC1) [ 2 , 30 , 31 , 32 , 51 , 55 ] and specific tissue markers that control myogenic differentiation, such as Myf5 [ 9 , 34 , 37 , 42 , 48 ], MyoD [ 48 , 56 , 58 ], and myogenin [ 48 , 56 , 57 , 58 , 60 ], were stimulated by epicatechin.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

New Trends to Treat Muscular Atrophy: A Systematic Review of Epicatechin

German,

Pomini,

Andreo

et al. 2024

Nutrients

View full text Add to dashboard Cite

Epicatechin is a polyphenol compound that promotes skeletal muscle differentiation and counteracts the pathways that participate in the degradation of proteins. Several studies present contradictory results of treatment protocols and therapeutic effects. Therefore, the objective of this systematic review was to investigate the current literature showing the molecular mechanism and clinical protocol of epicatechin in muscle atrophy in humans, animals, and myoblast cell-line. The search was conducted in Embase, PubMed/MEDLINE, Cochrane Library, and Web of Science. The qualitative analysis demonstrated that there is a commonness of epicatechin inhibitory action in myostatin expression and atrogenes MAFbx, FOXO, and MuRF1. Epicatechin showed positive effects on follistatin and on the stimulation of factors related to the myogenic actions (MyoD, Myf5, and myogenin). Furthermore, the literature also showed that epicatechin can interfere with mitochondrias’ biosynthesis in muscle fibers, stimulation of the signaling pathways of AKT/mTOR protein production, and amelioration of skeletal musculature performance, particularly when combined with physical exercise. Epicatechin can, for these reasons, exhibit clinical applicability due to the beneficial results under conditions that negatively affect the skeletal musculature. However, there is no protocol standardization or enough clinical evidence to draw more specific conclusions on its therapeutic implementation.

show abstract